3.8 Review

Hemophilia: In Review

期刊

PEDIATRICS IN REVIEW
卷 34, 期 7, 页码 289-295

出版社

AMER ACAD PEDIATRICS
DOI: 10.1542/pir.34-7-289

关键词

-

资金

  1. Baxter Healthcare Corp.
  2. Bayer HealthCare Pharmaceuticals
  3. Biogen Idec
  4. CSL Behring
  5. GTC Biotherapeutics
  6. Inspiration Bioscience
  7. NovoNordisk
  8. Pfizer

向作者/读者索取更多资源

Educational Gap General pediatricians rarely encounter bleeding in a neonate or a child, so it is important to know the genetics of hemophilia and to be aware of the clinical manifestations of bleeding disorders in order to appropriately identify those children at risk, ensure early diagnosis and treatment, and prevent complications. Objectives After completing this article, readers should be able to: 1. Describe the coagulation system and the basic physiology of blood clotting. 2. Know the genetics of hemophilia and be able to estimate the relative risk of hemophilia in carriers of the mutation. 3. Discuss the clinical manifestations and the potential complications of hemophilia. 4. List the initial laboratory studies needed to evaluate children who have bleeding. 5. Understand the role of comprehensive care in the treatment of patients with hemophilia.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

3.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据